Based on 1 analysts giving stock ratings to GT Biopharma Inc in the past month.
In the current month, GTBP has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GTBP average Analyst price target in the last month is 75.000.
Based on analysts' estimates, GTBP EPS is projected to reach -2.500 in FY2026Q3, following reported EPS of -2.957 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -2.96, while GT Biopharma IncGTBP's earnings per share (EPS) for the previous quarter was USD -2.78. EPS for the next quarter is expected at USD -2.50.